Organogenesis Holdings Inc.

NasdaqCM:ORGO 株式レポート

時価総額：US$326.1m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Organogenesis Holdings マネジメント

マネジメント 基準チェック /34

Organogenesis Holdings'の CEO はGary Gillheeneyで、 Jan2014年に任命され、 の在任期間は 10.42年です。 の年間総報酬は$ 6.24Mで、 14.6%給与と85.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.63%を直接所有しており、その価値は$ 2.08M 。経営陣と取締役会の平均在任期間はそれぞれ6.8年と3.6年です。

主要情報

Gary Gillheeney

最高経営責任者

US$6.2m

報酬総額

CEO給与比率14.6%
CEO在任期間10.4yrs
CEOの所有権0.6%
経営陣の平均在職期間6.8yrs
取締役会の平均在任期間3.6yrs

経営陣の近況

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 15
We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Recent updates

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 15
We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst

Jun 10

Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

May 21
Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

May 01
Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Apr 10
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Jan 04
These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

May 31
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Jan 19
Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio

Oct 18

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Sep 23
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Organogenesis gets FDA clearance for PuraPly MZ for wound healing

Aug 15

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors

Jul 28
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Jun 10
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Organogenesis Holdings: What Now

May 18

The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Earnings Yet

Mar 31
The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Earnings Yet

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Mar 04
These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Organogenesis Holdings (NASDAQ:ORGO) Seems To Use Debt Quite Sensibly

Nov 30
Organogenesis Holdings (NASDAQ:ORGO) Seems To Use Debt Quite Sensibly

CEO報酬分析

Organogenesis Holdings の収益と比較して、Gary Gillheeney の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2024n/an/a

US$6m

Dec 31 2023US$6mUS$909k

US$5m

Sep 30 2023n/an/a

US$13m

Jun 30 2023n/an/a

US$10m

Mar 31 2023n/an/a

US$13m

Dec 31 2022US$6mUS$883k

US$16m

Sep 30 2022n/an/a

US$59m

Jun 30 2022n/an/a

US$71m

Mar 31 2022n/an/a

US$83m

Dec 31 2021US$4mUS$835k

US$94m

Sep 30 2021n/an/a

US$62m

Jun 30 2021n/an/a

US$69m

Mar 31 2021n/an/a

US$43m

Dec 31 2020US$3mUS$823k

US$17m

Sep 30 2020n/an/a

-US$5m

Jun 30 2020n/an/a

-US$37m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019US$1mUS$819k

-US$39m

Sep 30 2019n/an/a

-US$46m

Jun 30 2019n/an/a

-US$48m

Mar 31 2019n/an/a

-US$58m

Dec 31 2018US$3mUS$798k

-US$65m

Sep 30 2018n/an/a

-US$60m

Jun 30 2018n/an/a

-US$52m

Mar 31 2018n/an/a

-US$32m

Dec 31 2017US$1mUS$780k

-US$9m

報酬と市場: Garyの 総報酬 ($USD 6.24M ) は、 US市場 ($USD 2.44M ) の同規模の企業の平均を上回っています。

報酬と収益: Garyの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Gary Gillheeney (69 yo)

10.4yrs

在職期間

US$6,244,671

報酬

Mr. Gary S. Gillheeney, Sr. has been the Chief Executive Officer and President of Organogenesis Holdings Inc. since 2014 and has been its Director since December 10, 2018 & serves as its Chair of the Board...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Gary Gillheeney
President10.4yrsUS$6.24m0.63%
$ 2.1m
David Francisco
Chief Financial Officer3.3yrsUS$1.63m0.048%
$ 157.1k
Patrick Bilbo
Chief Operating Officer6.8yrsUS$2.16m0.26%
$ 853.8k
Lori Freedman
Chief Administrative & Legal Officer7.4yrsUS$1.99m0.063%
$ 206.4k
Brian Grow
Chief Commercial Officer6.8yrsUS$1.92m0.078%
$ 255.4k
William Kolb
Secretaryno dataデータなしデータなし
Robert Cavorsi
Vice President of Strategy3.4yrsデータなしデータなし

6.8yrs

平均在職期間

57.5yo

平均年齢

経験豊富な経営陣: ORGOの経営陣は経験豊富で経験豊富です（平均在職期間は6.8年）。

取締役

名称ポジション在職期間報酬所有権
Gary Gillheeney
President5.5yrsUS$6.24m0.63%
$ 2.1m
Glenn Nussdorf
Director21.4yrsデータなし11.29%
$ 36.8m
Alan Ades
Director21.4yrsデータなし11.5%
$ 37.5m
Arthur Leibowitz
Lead Independent Director5.5yrsUS$291.46k0.10%
$ 336.0k
Robert Ades
Director3.6yrsデータなしデータなし
Jon Giacomin
Independent Director3.1yrsUS$265.00k0.068%
$ 221.0k
Michele Korfin
Independent Director2.1yrsUS$226.98k0.068%
$ 220.5k
Prathyusha Duraibabu
Independent Director2.6yrsUS$240.00k0.071%
$ 230.9k
David Erani
Director3.6yrsデータなしデータなし
Michael Driscoll
Independent Director2.3yrsUS$230.52kデータなし
Gilberto Quintero
Independent Director2.1yrsUS$226.98k0.068%
$ 220.5k

3.6yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: ORGOの 取締役会 は 経験豊富 であると考えられます ( 3.6年の平均在任期間)。